[1] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2015[J].CA Cancer J Clin,2015,65(1):5-29.
[2] AZZOLI C G,TEMIN S,ALIFF T,et al.2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage Ⅳ non-small-cell lung cancer[J].J Clin Oncol,2011,29(28):3825-3831.
[3] ETTINGER D S,WOOD D E,AKERLEY W,et al.Non-small cell lung cancer,version 6.2015[J].J Natl Compr Canc Netw,2015,13(5):515-524.
[4] AZZOLI C G,TEMIN S,GIACCONE G.2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage Ⅳ non-small-cell lung cancer[J].J Oncol Pract,2012,8(1):63-66.
[5] ZHAO T,WANG H J,ZHAO W W,et al.Gambogic acid improves non-small cell lung cancer progression by inhibition of mTOR signaling pathway[J].Kaohsiung J Med Sci,2017,33(11):543-549.
[6] ZHANG H Z,KASIBHATLA S,WANG Y,et al.Discovery,characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay[J].Bioorg Med Chem,2004,12(2):309-317.
[7] CHEN Q,YU Q,LIU Y,et al.Multifunctional selenium nanoparticles:chiral selectivity of delivering MDR-siRNA for reversal of multidrug resistance and real-time biofluorescence imaging[J].Nanomedicine,2015,11(7):1773-1784.
[8] YANG L,SHI T,LIU F,et al.REV3L,a promising target in regulating the chemosensitivity of cervical cancer cells[J].PLoS One,2015,10(3):334-352.
[9] MIRANDA H F,PUIG M M,PRIETO J C,et al.Synergism between paracetamol and nonsteroidal anti-inflammatory drugs in experimental acute pain[J].Pain,2006,121(1-2):22-28.
[10] HUANG J,ZHU X,WANG H,et al.Role of gambogic acid and NaI131 in A549/DDP cells[J].Oncol Lett,2017,13(1):37-44.
[11] CHEN P M,CHENG Y W,WU T C,et al.MnSOD overexpression confers cisplatin resistance in lung adenocarcinoma via the NF-κB/Snail/Bcl-2 pathway[J].Free Radic Biol Med,2015,79:127-137.
[12] WU D W,WU T C,WU J Y,et al.Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression[J].Oncogene,2014,33(35):4385-4395.
[13] NISHIOKA T,LUO L Y,SHEN L,et al.Nicotine increases the resistance of lung cancer cells to cisplatin through enhancing Bcl-2 stability[J].Br J Cancer,2014,110(7):1785-1792.
[14] LAN D,WANG L,HE R,et al.Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells[J].Am J Transl Res,2018,10(5):1295-1309.
[15] CHEN Y L,YANG T Y,CHEN K C,et al.Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers[J].Cell Oncol(Dordr),2016,39(5):411-433.
[16] LEO M,GOMES S,PEDRAZA-CHAVERRI J,et al.A mangostin and gambogic acid as potential inhibitors of the p53-MDM2 interaction revealed by a yeast approach[J].J Nat Prod,2013,76(4):774-778.
[17] KOSTER R,TIMMER-BOSSCHA H,BISCHOFF R,et al.Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway[J].Cell Death Dis,2011,2:148-159.
[18] TANG X,HU G,XU C,et al.HZ08 reverse the aneuploidy-induced cisplatin-resistance in Gastric cancer by modulating the p53 pathway[J].Eur J Pharmacol,2013,720(1-3):84-97.
[19] CHEE J L,SAIDIN S,LANE D P,et al.Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9[J].Cell Cycle,2013,12(2):278-288.
[20] SARIN N,ENGEL F,KALAYDA G V,et al.Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest[J].PLoS One,2017,12(7):81-99.
[21] GADHIKAR M A,SCIUTO M R,ALVES M V,et al.Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53[J].Mol Cancer Ther,2013,12(9):1860-1873.
[22] 郭晓彤,魏优蕾,雷加吉,等.藤黄酸对非小细胞肺癌A549细胞凋亡及Bcl-2、Bax、P53基因表达的影响[J].中国老年学杂志,2018,38(4):911-914. |